Showing 1831-1840 of 2526 results for "".
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- Glaukos Enters into a Collaboration and Marketing Agreement with Radius XRhttps://modernod.com/news/glaukos-enters-into-a-collaboration-and-marketing-agreement-with-radius-xr/2481728/Glaukos announced that it has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR wearable patient engagement and diagnostic system within the United States. Radius
- National Eye Institute Names Kapil Bharti New Scientific Directorhttps://modernod.com/news/kapil-bharti-is-neis-new-scientific-director/2481726/The National Eye Institute (NEI) has named Kapil Bharti was Scientific Director, effective May 2023. “Dr. Bharti is a world-class translational vision scientist, a thoughtful planner who understands interdisciplinar
- Astellas Enters License Agreement with 4D Molecular Therapeutics to Use Intravitreal R100 Vector for Rare Ophthalmic Targetshttps://modernod.com/news/astellas-enters-license-agreement-with-4d-molecular-therapeutics-4dmt-to-use-proprietary-intravitreal-r100-vector-for-rare-ophthalmic-targets/2481721/Astellas Pharma and 4D Molecular Therapeutics announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one genetic target implicated in rare monogenic o
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- IRIS and AEYE Health Announce Partnership to Provide AI Screening to Markethttps://modernod.com/news/iris-and-aeye-health-announce-partnership-to-provide-ai-screening-to-market/2481718/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with AEYE Health, an artificial intelligence company for retinal imaging and diagnostics. Under the agreement, IRIS will license AEYE Diagnostic Screening (AEYE-DS) from AEYE Health, which is an FDA-cleared AI technology that
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Mount Sinai Launches Center for Ophthalmic Artificial Intelligence and Human Healthhttps://modernod.com/news/mount-sinai-launches-center-for-ophthalmic-artificial-intelligence-and-human-health/2481706/The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first-of-its-kind in New York and one of the first in the United States. The Center is dedicated to advancing artificial intelligence (AI) in the field of ophthalm
- Bausch + Lomb to Acquire Xiidra from Novartishttps://modernod.com/news/bausch-lomb-will-acquire-xiidra/2481704/Bausch + Lomb announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5%. Xiidra is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DE